Lupin Q1 FY27: Sales Surge 33.3% to ₹82,172 Crore, PAT Rises 16% to ₹14,170 Crore
Lupin Limited reported Q1 FY27 results with sales up 33.3% YoY to ₹82,172 crore. PAT increased 16.0% to ₹14,170 crore. EBITDA grew 42.8% to ₹25,799 crore. U.S. sales surged 42.9% to ₹34,348 crore. India sales rose 13.9% to ₹23,796 crore.
The significant increase in key financial metrics like sales and profit, coupled with robust growth in major markets like the U.S. and India, is expected to have a high impact on investor sentiment and the company's stock.
The company reported strong year-on-year growth in sales, EBITDA, and PAT, along with positive commentary from the Managing Director, indicating a favorable financial performance.
Lupin Limited reported its financial results for the first quarter of FY2027, ending June 30, 2026. The company announced a significant 33.3% year-on-year increase in sales, reaching ₹82,172 crore (INR 82,172 Mn) compared to ₹61,638 crore (INR 61,638 Mn) in Q1 FY2026. Profit After Tax (PAT) for the quarter stood at ₹14,170 crore (INR 14,170 Mn), marking a 16.0% rise from ₹12,215 crore (INR 12,215 Mn) in the same period last year.
EBITDA saw a substantial increase of 42.8% to ₹25,799 crore (INR 25,799 Mn), with the EBITDA margin improving to 31.4% from 29.3% in Q1 FY2026. Profit Before Tax (PBT) also grew by 42.5% YoY to ₹20,174 crore (INR 20,174 Mn). The company highlighted strong growth across its key markets, with U.S. sales increasing by 42.9% to ₹34,348 crore (INR 34,348 Mn), contributing 42% of global sales. India sales grew by 13.9% to ₹23,796 crore (INR 23,796 Mn), accounting for 29% of global sales.
Investment in Research and Development for the quarter was ₹6,077 crore (INR 6,077 Mn), representing 7.4% of sales. The company received 6 ANDA approvals from the U.S. FDA and launched 3 new products in the U.S. market during the quarter. Mr. Nilesh Gupta, Managing Director, Lupin Limited, expressed satisfaction with the strong performance, attributing it to robust growth, operational excellence, and sustained investments in technology and innovation.
What to do with a filing like this
Lupin Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lupin Limited. Read the original for the full detail.